What exactly are mesenchymal stem cells?
MSCs are multipotent cells with self-renewal capacity, obtainable from various tissues: bone marrow, umbilical cord tissue, adipose tissue, among others.
They are characterized by low or no expression of histocompatibility markers, which makes them “immunoprivileged” that is, with a low risk of rejection if allogeneic (donor) cells are used.
In addition, they have immunomodulatory and anti-inflammatory properties and secrete growth factors, making them candidates for therapies in diseases with inflammatory or neurological components.
MSCs are not miracle cells, but their biology makes them suitable for exploration as a complementary treatment in conditions such as ASD, always under responsible protocols.
What does science say about the safety of MSCs in autism?
A recent systematic review identified multiple clinical studies that evaluated therapies with MSCs or other stem cells in patients with ASD: the results showed good safety profiles, with no significant increase in serious adverse events.
A 2022 meta-analysis concluded that, although the evidence is limited, “stem cell therapy could be safe and effective” in children with autism. In the studies analyzed, no statistically significant risk of adverse reactions was observed between the treated group and the control group.
In a phase I study published in 2020, intravenous infusion of MSCs derived from umbilical cord tissue in children was described as “safe and feasible.”
Therefore, based on the available scientific evidence, no serious recurrent risks have been reported, suggesting that the therapy has an acceptable safety profile under controlled conditions.
Origin, processing, and certifications: why it matters
Safety depends not only on the type of cell, but also on how they are obtained, processed, and administered. Key points include:
Source of MSCs: many studies use MSCs derived from umbilical cord blood (UC-MSCs), either from altruistic donations or authorized banks. These have advantages due to their cellular youth and lower immunological risk.
Laboratory and quality standards: Controls must be performed for viability, purity, sterility, and cell markers, and ethical and health regulations must be complied with.
Medical protocol and follow-up: From the preliminary evaluation of the patient, appropriate dosage, and route of administration to medium- and long-term post-infusion monitoring. This minimizes risks and allows adverse effects to be documented.
At Angel's Hope, a serious protocol would include these steps, in addition to a complete medical evaluation before any MSC treatment—something essential to ensure quality and ethics.
How does Angel's Hope guarantee the safety of the treatment?
A responsible center such as Angel's Hope must consider:
Thorough prior medical evaluation: complete medical history, risk and benefit assessment, compatibility analysis.
Use of high-quality MSCs: ideally derived from umbilical cord blood, certified by accredited banks, with viability, purity, and sterility controls.
Standardized medical protocol: dosage, route of administration, timing, data recording.
Rigorous post-treatment follow-up: monitoring of immediate, medium, and long-term effects; recording of symptoms, improvements, or adverse events.
Transparency with families: explaining realistic expectations, variability, and the need for complementary therapies (educational, occupational, behavioral).
This professional and ethical approach helps maximize potential benefits and minimize risks—and reinforces the trustworthiness of the treatment.
Who might this treatment be suitable (or unsuitable) for?
Potential candidates
Children with ASD whose parents are looking for a complementary approach after conventional therapies.
Young patients, when brain plasticity is greater—although there is still no absolute consensus.
Families willing to undergo rigorous monitoring and with realistic expectations.
Situations requiring caution or not recommended
People with severe comorbidities, active autoimmune diseases, or without medical follow-up.
When the “clinic” cannot guarantee adequate standards of quality/certification.
If a definitive “cure” is expected with a single infusion—this currently has no solid backing.
It is essential that the decision be informed, conscious, and accompanied by serious medical supervision.
Current scientific evidence suggests that mesenchymal stem cell therapy may have an acceptable safety profile when administered under responsible protocols, with high-quality MSCs and adequate follow-up. However, it also makes clear that there is no guaranteed cure for autism; results vary and depend on many factors.
If you would like to explore whether this type of treatment could be right for your child—with all the seriousness, ethics, and support it deserves—at Angel's Hope, we are available to evaluate your case professionally. Schedule a consultation with our specialized team for a personalized assessment.
Bibliography::
Qu J., et al. Efficacy and Safety of Stem Cell Therapy in Children With Autism Spectrum Disorders: A Meta-Analysis. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9114801
Sun J. M., et al. Infusion of human umbilical cord tissue mesenchymal stromal cells in young children: Phase I study. 2020. stemcellsjournals.onlinelibrary.wiley.com
Liu Q., et al. Rational use of mesenchymal stem cells in the treatment of autism spectrum disorder. 2019.https://pmc.ncbi.nlm.nih.gov/articles/PMC6397804
Tamouza R., et al. Mesenchymal stromal cells: immunoregulatory properties and rationale for use in ASD. 2022.https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2022.809686
Espinoza F., et al. Escenario actual y perspectivas de la terapia con células madre mesenquimales. 2016. https://www.scielo.cl/scielo.php?pid=S0034-98872016000200011&script=sci_arttext
Akat A., et al. Cell therapies for autism spectrum disorder: a systematic review of clinical trials. 2023.https://mecp.springeropen.com/articles/10.1186/s43045-023-00363-9